In the persistence and adherence analysis, which looked at 28 studies including 267,542 patients, Amgen found that 69% of ...

NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.

Johnson & Johnson is a global leader in the pharmaceutical and medical device industries. Its key products include ...

Lilly leads the obesity medicine race. Novo built the metabolic drug market. Amgen adds a biotech challenger angle. Obesity ...

Chief District Judge Thomas Kleeh denied Regeneron Pharmaceuticals, Inc.‘s (NASDAQ:REGN) effort to prevent the sale of Amgen Inc‘s (NASDAQ:AMGN) Eylea biosimilar. Regeneron filed a notice of its ...

Amgen’s roller coaster ride known as Tepezza is ascending again. Is the thyroid eye disease (TED) treatment finally gaining momentum that is sustainable? In the second quarter, Tepezza generated $479 ...

The district court denied Amgen’s motion to dismiss on February 10, 2023, concluding that Regeneron sufficiently alleged state and federal antitrust claims, such as “anticompetitive conduct under an ...

Aug 25 (Reuters) - Royalty Pharma (RPRX.O), opens new tab has agreed to buy a royalty interest in Amgen's (AMGN.O), opens new tab drug for small cell lung cancer from BeOne Medicines (688235.SS), ...

Amgen Inc.’s AMGN Japanese partner Kissei Pharmaceutical Co., Ltd. said it has started information-sharing activities in Japan, urging healthcare professionals to carefully evaluate the use of Tavneos ...

Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a ...

Drug pricing pressure is pushing major pharmaceutical companies to rethink pipelines, global revenue mix, and long-term branded medicine strategies.

Kissei Pharmaceutical Co. announced that 20 individuals who took its vasculitis treatment drug Tavneos have died in Japan, ...